The Legal Examiner Affiliate Network The Legal Examiner The Legal Examiner The Legal Examiner search instagram avvo phone envelope checkmark mail-reply spinner error close The Legal Examiner The Legal Examiner The Legal Examiner
Skip to main content

Xarelto Bleeding Injury Lawsuit $27M Verdict. According to Bloomberg news report, Johnson & Johnson and its partner Bayer AG were found liable for a woman’s Xarelto bleeding injury.

The Pennsylvania jury slapped the pharmaceutical giant companies and ordered them to pay almost $28 million in damages.

Plaintiff nearly bled to death

According to Lynn Hartman, she took Xarelto, sold by J&J’s Janssen Pharmaceuticals unit, for more than a year before being hospitalized in 2014 with severe gastrointestinal bleeding.

The jury noted $1.8 million in actual damages and $26 million in punitive damages, to punish the companies for their wrongful acts.

What is Xarelto?

Xarelto belongs to a new class of oral anticoagulants drugs replacing Coumadin, which has been the go-to anticoagulant since the 1960s.

Critics of Xarelto stress that the drug has no antidote, so it puts some users at high risk for bleeding out if they suffer an injury. Coumadin’s blood-thinning effects can be reversed.

While Xarelto is the market leader for new generation anticoagulants, Boehringer’s Pradaxa anticoagulant has one major advantage over the others: A reversal agent was approved for it in a case of uncontrolled bleeding.

Xarelto Bleeding Injury Lawsuits

Johnson & Johnson and Bayer won the first three cases to come to trial in federal court after juries found the drug was safe and the companies properly warned about Xarelto’s bleeding risks.

The drug companies are exposed to more than 20,000 Xarelto suit injury claims.

Xarelto linked to patient deaths

Xarelto has been linked to at least 370 deaths, according to U.S. Food and Drug Administration reports.

Xarelto is a Blockbuster drug

Xarelto is Bayer’s top-selling product, raked in $3.2 billion in sales last year. Bayer is headquartered in Germany. Xarelto is J&J’s third-largest seller, grabbing $2.3 billion in sales in 2016.

During the trial, ex-FDA Chief David Kessler told the Philadelphia Common Pleas Court that the companies’ Xarelto warning labels minimized the drug’s bleeding risks and didn’t warn doctors that some patients would be at higher risks for bleed outs.

The case is Lynn Hartman v. Janssen Pharmaceuticals Inc., Case No. 160503416, Court of Common Pleas of Philadelphia County, Pennsylvania.

If you or a loved one used Xarelto and have suffered injuries or wrongful death with the medication, contact the Dr. Shezad Malik Law Firm to learn more about your legal rights. You can speak with one of our team by calling toll-free at 888-210-9693, 214-390-3189 or by filling out the case evaluation form on this page.

Comments for this article are closed.